IO Biotech

• IO Biotech's innovative T-win technology delivers dual-acting cancer vaccines that target both tumor cells and immune-suppressive cells, transforming hostile tumor microenvironments into immune-friendly ones. • The company's lead candidate Cylembio (IO102/IO103) has received FDA Breakthrough Therapy designation and demonstrated an 80% objective response rate in advanced melanoma when combined with nivolumab. • Phase 3 trial results for Cylembio combined with pembrolizumab in metastatic melanoma are expected in Q3 2025, with a Biologics License Application planned for submission to the FDA by the end of this year.

• IO Biotech has completed enrollment in its Phase 2 basket trial (IOB-032/PN-E40) evaluating IO102-IO103 in combination with pembrolizumab. • The trial includes patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) receiving neoadjuvant/adjuvant treatment. • Initial data from the Phase 2 trial, which enrolled 93 patients across multiple sites, is expected in 2025. • The primary endpoint is major pathological response (MPR), with secondary endpoints including pCR, ORR, DFS, EFS, and safety.

• IO Biotech received a Nasdaq warning for its stock price falling below $1.00 for 30 consecutive days, risking delisting. • The company has until June 2025 to regain compliance by maintaining a stock price above $1.00 for at least 10 days. • Recent data from a Phase 2 trial of IO102-IO103 showed potential in treating metastatic non-small cell lung cancer. • A €57.5 million loan from the EIB aims to advance IO Biotech's cancer vaccine development, extending financial runway into Q2 2026.

• The FDA granted fast-track approval to Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, for metastatic melanoma patients who have failed other treatments, marking a significant advancement in cellular immunotherapy. • Neoadjuvant immunotherapy has become the standard of care for stage III melanoma patients with resectable tumors, as highlighted at the European Society for Medical Oncology (ESMO) Congress. • Over 170 melanoma pipeline therapies are under development by 150+ companies, including IO Biotech, Moderna, Merck, and BioNTech, targeting various stages and mechanisms of the disease.

• IO Biotech's Phase 2 trial of IO102-IO103 with pembrolizumab demonstrates a 44.4% overall response rate in PD-L1 high recurrent or metastatic SCCHN patients. • The combination therapy shows an encouraging median progression-free survival of 6.6 months and a disease control rate of 66.7% in SCCHN. • The safety profile of IO102-IO103 with pembrolizumab is consistent with previous studies, showing no new systemic toxicity concerns. • These results support further investigation of IO102-IO103 plus pembrolizumab as a first-line treatment for advanced head and neck cancer.

• IO Biotech's Phase III trial of IO102-IO103 with pembrolizumab for advanced melanoma will continue following IDMC review. • The IDMC found no new safety signals, supporting the ongoing evaluation of the therapeutic vaccine combination. • The primary endpoint, progression-free survival, is projected to be reached in the first half of 2025. • The trial compares IO102-IO103 plus pembrolizumab to pembrolizumab alone in previously untreated patients.